Indian journal of psychiatry · 2026
Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects - A randomized controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prakash Anand, Mahapatra Pranab, Pattnaik Jigyansa I, Panda Udit K, Das Sudipta K
Аннотация
BACKGROUND: The 4-12 week lag period of conventional antidepressants creates critical vulnerability in severe depression, with peak suicide risk during the first month. While ketamine research has focused on treatment-resistant populations, its potential to eliminate this lag period in non-treatment-resistant severe depression remains unexplored.
AIMS: To evaluate whether add-on intravenous ketamine eliminates the treatment lag period in severe non-treatment-resistant major depressive disorder and assess rapid antidepressant and anti-suicidal effects.
METHODS: A randomized, double-blind, placebo-controlled trial was conducted at a tertiary care hospital from October 2020 to September 2022. Forty patients with severe MDD (HAM-D ≥19) received either ketamine (0.5 mg/kg IV, n = 19) or placebo (n = 21) as add-on therapy over 4 infusions on days 1, 3, 5, and 8. The primary outcome was ≥50% HAM-D reduction at day 12. Secondary outcomes included suicidal ideation using the Beck Scale for Suicidal Ideation (BSSI) and global functioning improvement.
RESULTS: Primary response rate was 58% versus 29% in placebo (P < 0.05), yielding a number needed to treat of 3.4. Significant HAM-D improvement occurred from day 2 onwards (P < 0.05). Complete suicidal ideation resolution occurred by day 5 in the ketamine group versus persistent ideation in placebo (P < 0.001). Patients with anxiety features showed 0% treatment completion versus 93% in non-anxious patients. Effects were sustained at 4-week follow-up.
CONCLUSIONS: This pilot randomized controlled trial provides preliminary evidence for rapid antidepressant and anti-suicidal effects of add-on intravenous ketamine in severe non-treatment-resistant major depression; findings require confirmation in an adequately powered trial.
AIMS: To evaluate whether add-on intravenous ketamine eliminates the treatment lag period in severe non-treatment-resistant major depressive disorder and assess rapid antidepressant and anti-suicidal effects.
METHODS: A randomized, double-blind, placebo-controlled trial was conducted at a tertiary care hospital from October 2020 to September 2022. Forty patients with severe MDD (HAM-D ≥19) received either ketamine (0.5 mg/kg IV, n = 19) or placebo (n = 21) as add-on therapy over 4 infusions on days 1, 3, 5, and 8. The primary outcome was ≥50% HAM-D reduction at day 12. Secondary outcomes included suicidal ideation using the Beck Scale for Suicidal Ideation (BSSI) and global functioning improvement.
RESULTS: Primary response rate was 58% versus 29% in placebo (P < 0.05), yielding a number needed to treat of 3.4. Significant HAM-D improvement occurred from day 2 onwards (P < 0.05). Complete suicidal ideation resolution occurred by day 5 in the ketamine group versus persistent ideation in placebo (P < 0.001). Patients with anxiety features showed 0% treatment completion versus 93% in non-anxious patients. Effects were sustained at 4-week follow-up.
CONCLUSIONS: This pilot randomized controlled trial provides preliminary evidence for rapid antidepressant and anti-suicidal effects of add-on intravenous ketamine in severe non-treatment-resistant major depression; findings require confirmation in an adequately powered trial.